Gerwin Huls
- Hematology top 0.5%
- Acute Myeloid Leukemia Research 59
- Hematopoietic Stem Cell Transplantation 24
- Multiple Myeloma Research and Treatments 13
- Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 16
- Oncology top 2%
- Immunology top 5%
- Immune Cell Function and Interaction 12
- Molecular Biology top 5%
- Epigenetics and DNA Methylation 11
- Histone Deacetylase Inhibitors Research 8
-
- Lymphoma Diagnosis and Treatment 11
- Co-authors
- Hans CleversMarc van de WeteringJan MeeldijkJennifer RobertsonElena SanchoJeffrey T. HendersonEduard BatlleTony Pawson
- Cited by
- HematologyGeneticsOncology
- Partner nations
- NetherlandsGermanyBelgium
In The Last Decade
Gerwin Huls
108 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Hematology 1.3k
- Genetics 435
- Oncology 1.1k
- Immunology 749
- Molecular Biology 1.9k
Countries citing papers authored by Gerwin Huls
This map shows the geographic impact of Gerwin Huls's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerwin Huls with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerwin Huls more than expected).
Fields of papers citing papers by Gerwin Huls
This network shows the impact of papers produced by Gerwin Huls. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerwin Huls. The network helps show where Gerwin Huls may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerwin Huls, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 7 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 28 | |
| 9 | 2023 | 7 | |
| 10 | 2023 | 5 | |
| 11 | 2023 | 7 | |
| 12 | 2022 | 29 | |
| 13 | 2022 | 2 | |
| 14 | Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndromebreakdown → | 2022 | 159 |
| 15 | 2021 | 7 | |
| 16 | 2021 | 16 | |
| 17 | 2019 | 15 | |
| 18 | 2011 | 139 | |
| 19 | 2010 | 16 | |
| 20 | 2004 | 35 |
About Gerwin Huls
Gerwin Huls is a scholar working on Hematology, Genetics and Immunology, having authored 115 papers that have together received 3.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (59 papers), Hematopoietic Stem Cell Transplantation (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Multiple Myeloma Research and Treatments (13 papers), Immune Cell Function and Interaction (12 papers), Epigenetics and DNA Methylation (11 papers), Lymphoma Diagnosis and Treatment (11 papers) and Histone Deacetylase Inhibitors Research (8 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (435 citations) and Oncology (1.1k citations). Gerwin Huls has collaborated with scholars based in Netherlands, Germany and Belgium. Frequent co-authors include Hans Clevers, Marc van de Wetering, Jan Meeldijk, Jennifer Robertson, Elena Sancho, Jeffrey T. Henderson, Eduard Batlle, Tony Pawson, Elisabeth G.E. de Vries and Urszula Domańska. Their work appears in journals such as Blood, Blood Advances, Haematologica, HemaSphere and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.